Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report published on Wednesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.16) EPS, FY2026 earnings at ($1.36) EPS, FY2027 earnings at ($1.35) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($0.95) EPS.

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $8.63.

Fulcrum Therapeutics Price Performance

FULC stock opened at $3.59 on Wednesday. Fulcrum Therapeutics has a 52-week low of $2.86 and a 52-week high of $13.70. The company’s 50 day simple moving average is $4.11 and its 200-day simple moving average is $4.57. The firm has a market capitalization of $193.64 million, a P/E ratio of -11.58 and a beta of 2.03.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). Sell-side analysts predict that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its position in Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock worth $2,032,000 after acquiring an additional 393,202 shares in the last quarter. State Street Corp grew its position in Fulcrum Therapeutics by 61.4% in the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after acquiring an additional 638,955 shares in the last quarter. Barclays PLC grew its position in Fulcrum Therapeutics by 367.1% in the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock worth $443,000 after acquiring an additional 97,565 shares in the last quarter. Braidwell LP bought a new stake in Fulcrum Therapeutics in the third quarter worth approximately $3,817,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fulcrum Therapeutics in the third quarter worth approximately $474,000. 89.83% of the stock is owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.